Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150783 | 0.92 | CD274 (0.85) | SMN1; SMN2ALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL487964 | 0.91 | CD274 (0.84) | SMN1; SMN2ALDH1A1KDM4EHPGDCD274 | |
| SCHEMBL10720845 | 0.90 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL3641780 | 0.89 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL1384427 | 0.87 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL10723691 | 0.87 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL763452 | 0.86 | HTT (0.78) | SMN1; SMN2ALDH1A1KDM4ETSHRCD274 | |
| SCHEMBL3034681 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL12459935 | 0.86 | CD274 (0.79) | SMN1; SMN2ALDH1A1KDM4ETSHRHPGD | |
| Eprobemide SCHEMBL570896 | 0.86 | ALDH1A1 (0.85) | SMN1; SMN2ALDH1A1KDM4ETSHRCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| CN-103408540-A | 2-imidazole ring-substituted thiophene PLK1 (Polo-like kinase 1) inhibitors and applications thereof | UNIV CHINA PHARMA | 2013-11-27 | — | — | CN | claimed |
| JP-4695588-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| JP-2006519232-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| WO-2015032286-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| EP-2509946-B1 | SPIRO INDOLE-CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-04-16 | — | — | EP | disclosed |
| CN-103408540-A | 2-imidazole ring-substituted thiophene PLK1 (Polo-like kinase 1) inhibitors and applications thereof | UNIV CHINA PHARMA | 2013-11-27 | — | — | CN | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | SMN1; SMN2 4123/4885ALDH1A1 4309/4885KDM4E 2279/4885 |
| US-20240092790-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | SMN1; SMN2 4674/4885ALDH1A1 1029/4885KDM4E 899/4885 |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | SMN1; SMN2 4020/4885ALDH1A1 554/4885KDM4E 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.